Eli Lilly and Company (LLY)vsOmada Health, Inc. Common Stock (OMDA)
LLY
Eli Lilly and Company
$1,354.00
-0.79%
HEALTHCARE · Cap: $1.26T
OMDA
Omada Health, Inc. Common Stock
$15.09
-20.37%
HEALTHCARE · Cap: $1.15B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 27813% more annual revenue ($86.46B vs $309.76M). LLY leads profitability with a 31.9% profit margin vs 1.4%. LLY trades at a lower P/E of 46.0x. LLY earns a higher WallStSmart Score of 74/100 (B).
LLY
Strong Buy74
out of 100
Grade: B
OMDA
Hold40
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Revenue surging 43.1% year-over-year
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 30.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
1.4% margin — thin
Operating margin of 4.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bull Case : OMDA
The strongest argument for OMDA centers on Revenue Growth. Revenue growth of 43.1% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses.
Bear Case : OMDA
The primary concerns for OMDA are EPS Growth, Market Cap, Profit Margin. A P/E of 78.0x leaves little room for execution misses. Thin 1.4% margins leave little buffer for downturns.
Key Dynamics to Monitor
LLY profiles as a growth stock while OMDA is a hypergrowth play — different risk/reward profiles.
OMDA is growing revenue faster at 43.1% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (74/100 vs 40/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Omada Health, Inc. Common Stock
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Omada Health, Inc. provides a range of virtual care programs in the United States. The company is headquartered in San Francisco, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?